Journal article

Clinical pathways and outcomes of patients with Barrett's esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008-2016

Renhua Na, Kyoko Miura, Suzanne O'Brien, Guy D Eslick, Bradley J Kendall, Luke F Hourigan, Michael Bourke, Michael R Cox, Laal Farrokhzadi, Angelique J Levert-Mignon, Andrew P Barbour, Nicholas J Clemons, Cuong P Duong, Reginald Lord, Wayne A Phillips, David Watson, David C Whiteman

DISEASES OF THE ESOPHAGUS | OXFORD UNIV PRESS INC | Published : 2021

Abstract

BACKGROUND: Clinical services for Barrett's esophagus have been rising worldwide including Australia, but little is known of the long-term outcomes of such patients. Retrospective studies using data at baseline are prone to both selection and misclassification bias. We investigated the clinical characteristics and outcomes of Barrett's esophagus patients in a prospective cohort. METHODS: We recruited patients diagnosed with Barrett's esophagus in tertiary settings across Australia between 2008 and 2016. We compared baseline and follow-up epidemiological and clinical data between Barrett's patients with and without dysplasia. We calculated age-adjusted incidence rates and estimated minimally ..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia


Awarded by Cancer Council NSW


Awarded by NHMRC


Awarded by Department of Health and Human Services through the Victorian Cancer Agency, Victoria, Australia


Awarded by NHMRC Centres of Research Excellence


Funding Acknowledgements

This study was funded by the National Health and Medical Research Council (NHMRC) of Australia (NHMRC APP1040947) and Cancer Council NSW (SRP 08-04). DCW was supported by NHMRC research fellowships (APP1155413, APP1058522). RN and KM were supported by NHMRC Centres of Research Excellence (Grant APP1040947). KM was supported by NHMRC Program (Grant Nos 552429, 1073898. NJC was supported by a Fellowship (MCRF16002) from the Department of Health and Human Services acting through the Victorian Cancer Agency, Victoria, Australia. We thank Dr Juliana Andrici for setting-up the first phase of the Clinical Follow-Up Study.